Biotech companies are tantalizingly near unraveling the mysteries of reminiscence. Six such setups chart the thoughts-altering effects of dozens of compounds a month. This simulates the electrochemical modifications that happen in brain cells when a new reminiscence is created. Inside a small lab in an nameless office park off the Garden State Parkway in northern New Jersey, researchers probe the molecular intricacies of reminiscence. Most have little effect, but a few medication fit a cherished profile: helping the disembodied neurons type stronger, longer-lasting connections. A robotic pump drips experimental drugs by means of plastic tubes onto the brain cells, whereas other electrodes measure how every drug alters their exercise. Memory Pharmaceuticals, the closely held biotech agency doing this work, is at the forefront of an intense scientific race to plot the primary efficient memory-enhancing drug. Tiny metallic electrodes zap minute jolts of electricity at precise intervals into slices of rat mind suspended in nutrient broth in plastic lab dishes. On the way are medicine to help fading minds remember and let haunted ones neglect.At the guts of each males's research is a startling reality: The fundamental mechanics of reminiscence formation in humans aren't a lot different from these of snails, flies and different easy creatures. About this time, scientists bought their first serious clue to how and where memories are formed. Brain cells seem to be related in all animals; the difference is in the complexity of the wiring that links them. His seizures went away and his reasoning capacity was intact, however he might now not recall any new details for longer than a number of seconds. A 27-yr-outdated affected person, identified in medical literature solely as H.M., had extreme epilepsy. In an try to cure it, surgeons in 1953 removed his hippocampus, a small ridge in the center of the mind. Early on, after graduating from Harvard with plans to become a psychoanalyst, he detoured into research after becoming fascinated with new strategies for probing the electrical activity of mind neurons. Tully. This wasn't at all obvious when Kandel received started in the late 1950s, when most scientists assumed the human brain was far more advanced.Human trials might begin next 12 months. Depending on their mechanism of action, memory medication might work in the remedy of hundreds of thousands of people with head trauma, Down's syndrome or mental retardation. Several million people have so-called mild cognitive impairment, and Pfizer and J&J now are testing whether or not this may be handled by their already-authorized Alzheimer's drugs, Aricept and Reminyl. Kandel's archrival on this race is 25 years younger and a bit more brazen: Timothy Tully, 47, a researcher at Cold Spring Harbor Laboratory and a founder of privately held Helicon Therapeutics in Farmingdale, N.Y. He hopes to begin human trials in two years. viagra use in dogs and huge drug corporations, including Merck, Johnson & Johnson and GlaxoSmithKline, also are in pursuit. The primary users would be the four million Americans with Alzheimer's disease, however finally the market may be far larger. The market ratchets up quickly from there. The prize is a stake in what will likely be one in all the subsequent large world drug markets.The idea has long been the stuff of science fiction, but now researchers are decoding the molecular details of how reminiscences are formed and how they're misplaced. They are tantalizingly near making a kind of Viagra for the mind: a chemical that reinvigorates an organ that has light with age. This new era of medicine may mend memory loss in the seriously sick or the merely absentminded. They've taken a crucial first step: figuring out the genes and proteins inside brain cells that regulate reminiscence formation. Eric Kandel, 72, the elder statesman of the sector, a Columbia University researcher who founded Memory Pharmaceuticals in 1998 and received the Nobel Prize in 2000. He started his work in the 1950s, when most researchers considered it as futile. At his lab chemists have concocted prototypes that counteract age-related memory loss, making grizzled mice race via mazes as shortly as youthful ones.The effect fades away minutes or hours later. But cyclic-AMP is only a messenger; it would not churn out the brand new proteins essential for constructing long-time period recollections. Even these, however, erode with time. Long-term memories are extra like marriages, cemented in place for weeks or years with new proteins that reinforce the synapses connecting the cells. By the mid-1970s Kandel was a star. Though liable to brutal candor in describing the work of lesser scientists, he mesmerized colleagues with sweeping lectures, encyclopedic knowledge and charming wit. The advent of biotech within the late 1970s allowed Kandel and others to explore reminiscence on a molecular stage. It sits contained in the surface of a cell and springs into action when signaled by different cells, activating proteins that briefly enhance the connection between two nerve cells. Kandel helped present that a messenger called cyclic-AMP (adenosine monophosphate) played a central function in reminiscence formation. Johns Hopkins neuroscientist Solomon Snyder. That was crucial: Once the molecular workings are understood, drug targets become easier to search out.